Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, launched Dobutamine Injection, USP, in a 250mg/20mL vial in the US. With this launch, Hikma’s U.S. portfolio of sterile injectable medicines now exceeds 150 products spanning a wide range of therapeutic areas and dosage forms.

In addition, Hikma now markets approximately 30 sterile injectable medicines in Canada, with plans to launch up to 13 additional products this year. The company has also launched Hikma 503B, a new sterile compounding business focused on providing high-quality, ready-to-administer injectable medications that are customized to the specific needs of patients in the U.S.

“Our portfolio of more than 150 injectable medicines has expanded by more than 50 percent over the last three years, driven by customer needs, an expansion of our capabilities and product offerings, and the continued recognition of Hikma as a reliable, high-quality supplier of sterile injectable medicines,” said Riad Mishlawi, president, Injectables, Hikma. “As a top-three supplier of generic injectable medicines by volume in the US2, we are proud of the important role we play in the US health care system. We are committed to further growing our portfolio and capabilities and continuing to supply essential medicines to US hospitals, doctors, and patients.”